Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Precision Biosciences (DTIL) Non-Current Debt (2024 - 2025)

Precision Biosciences (DTIL) has disclosed Non-Current Debt for 2 consecutive years, with $22.4 million as the latest value for Q3 2025.

  • On a quarterly basis, Non-Current Debt changed 0.43% to $22.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was $22.4 million, a 0.43% change, with the full-year FY2024 number at $22.3 million, changed N/A from a year prior.
  • Non-Current Debt was $22.4 million for Q3 2025 at Precision Biosciences, roughly flat from $22.4 million in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $22.4 million in Q3 2025 to a low of $22.3 million in Q3 2024.